Multiple Sclerosis News

Stem Cells Used to Treat Secondary Progressive Patients in Clinical Trial

What may work better than existing drugs to treat severe multiple sclerosis? Stem cells. A phase 2 clinical study from an international group of research centers compared head-to-head autologous hematopoietic stem cell transplantation (AHSCT) and mitoxantrone in treating patients with secondary progressive or relapsing-remitting multiple sclerosis. The findings showed that…

Creative Medical Seeks Patent for Stem Cell Therapy for MS

Phoenix, Arizona-based Creative Medical Health (CMH) has just announced it has submitted a patent application for its proprietary mesenchymal stem cell pipeline product, indicated for autoimmune diseases. The company is already preparing to launch the product into its first line of clinical tests, which will…

Novel Antibody Drug Candidate From Chinese Drug Developer Shows Promise For Treating MS

MicroConstants China, Inc., a company that provides preclinical, clinical, and consulting services to biotechnology and pharmaceutical companies, has just announced it has acquired international rights to the development of AA98 antibody pipeline products, indicated for the treatment of several types of cancer, multiple sclerosis, and age related macular degeneration…

Amarantus Acquires DioGenix to Bolster New MS Diagnostic Division

Amarantus BioScience Holdings, Inc. has announced the acquisition of DioGenix, Inc., which will be merged as a new foundational asset into a growing neuro-diagnostic division at Amarantus called Amarantus Diagnostics. Amarantus BioScience is dedicated to developing novel neurological diagnostic tests and therapy options in the fields of neurology, psychiatry, ophthalmology and regenerative diseases, including multiple…

Researchers Study Device to Improve Balance for MS Patients

Multiple sclerosis (MS) patients often experience difficulty with balance and fear falling, which may prevent them from being social or participating in exercise and community activities, affecting their quality of life. However, a pioneering study conducted at the University of Massachusetts Amherst is looking to understand the role of…

Plegridy for Relapsing MS Now Approved in Scotland

The Scottish Medicines Consortium has just approved Biogen Idec’s Plegridy (peg interferon beta-1a) for the treatment of relapsing multiple sclerosis (MS) in patients between 18 to 65 years old, making the Consortium the first United Kingdom-based regulatory body to endorse the disease-modifying drug on the…

A Step Toward Multiple Sclerosis Treatment? Phase 2 ANTI-LINGO-1 Results Announced

Biogen Idec, a Cambridge Massachusetts Biotechnology company, has released results from its Phase 2 acute optic neuritis (AON) RENEW trial. The trial tested anti-LINGO-1, a medication that restores myelin — a fatty substance that facilitates nerve cell impulses by wrapping around them and providing insulation. The trial results indicate that anti-LINGO-1…

Multiple Sclerosis Risk Does not Increase with HPV Vaccine According to Study

Human papillomavirus (HPV) vaccination can help protect against several health problems, including cervical cancers in women. Some reports have raised concerns however, that the vaccine might actually increase the risk of developing multiple sclerosis. A study entitled “Quadrivalent HPV Vaccination and Risk of Multiple Sclerosis and Other…

Top 14 Multiple Sclerosis Stories of ’14

Given the fact that MS is a chronic, progressive, and disabling disease for which there is no cure, the multiple sclerosis community is always looking forward to the latest news regarding new therapies, devices or scientific findings about treating and curing the disease. These are the top 14 news stories of 2014 from…

New MS Study Seeks To Understand How Inflammation Causes Neuronal Damage in Multiple Sclerosis

A team of researchers from Italy recently examined if p53 genetic variants influence synaptic and toxic effects of cytokines in the neurodegenerative processes that occurs in Multiple Sclerosis. The study, entitled “Interleukin-1β causes excitotoxic neurodegeneration and multiple sclerosis disease progression by activating the apoptotic protein p53,” was recently published…

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These audio news stories give our readers an alternative option for accessing information important for them.

Listen Here